In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii.
about
Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment OptionsAntibiotic-resistant gram-negative bacterial infections in patients with cancer.Extensively drug-resistant Acinetobacter baumannii in a Thai hospital: a molecular epidemiologic analysis and identification of bactericidal Polymyxin B-based combinations.Activity of antimicrobial combinations against KPC-2-producing Klebsiella pneumoniae in a rat model and time-kill assay.Acinetobacter baumannii strains isolated from patients in intensive care units in Goiânia, Brazil: Molecular and drug susceptibility profiles.Multilocus Sequence Typing Analysis of Carbapenem-Resistant Acinetobacter baumannii in a Chinese Burns Institute.Synergistic combinations of polymyxins.Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii.Combination therapy in severe Acinetobacter baumannii infections: an update on the evidence to date.Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens.Antibacterial activity of human simulated epithelial lining fluid concentrations of amikacin inhale alone and in combination with meropenem against Acinetobacter baumannii.High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii.The Spider Venom Peptide Lycosin-II Has Potent Antimicrobial Activity against Clinically Isolated Bacteria.Tigecycline: Alone or in combination?Resurgence of Polymyxin B for MDR/XDR Gram-Negative Infections: An Overview of Current Evidence.Genetic Variability of AdeRS Two-Component System Associated with Tigecycline Resistance in XDR-Acinetobacter baumannii Isolates.In vitro potential of Lycosin-I as an alternative antimicrobial drug for treatment of multidrug-resistant Acinetobacter baumannii infections.Antibiotic resistance of pathogenic Acinetobacter species and emerging combination therapy.Carbapenem Resistance: A Review.
P2860
Q30235064-310FC6DB-E5BE-4918-980C-433B9BBC588BQ34999880-3F59F2F7-ACB9-40D4-A659-6D7F3D94C355Q35041371-566EFBF6-2016-4D64-9326-7BB2C0F8BDF5Q35746001-ACDA6E79-1602-4CF7-8C59-27A43368B843Q36364166-513C998B-9215-497B-9E97-08FDD013B1D2Q37402130-4E9AF7BC-1C47-46C3-B58B-F16402E6AC80Q37586960-3F26E832-3AFF-4899-B672-EC601D1AB05BQ37600495-13CFC119-5C17-4F82-B2CF-7E60BB8A8FCAQ38232199-E14CFCFF-B1A3-4027-B85E-61DDCAB9521EQ38262205-E1C56E8B-C471-4DF3-B33B-3E45197AF79EQ38652103-A16164BF-7C9C-4E66-A347-C976F8D5279EQ39170967-52D197AF-0B74-42F3-88D9-EDF9D22AB42CQ39809838-0E2339A4-3DA4-4F44-9CFE-81291C7C241EQ39916184-855BF244-EBE2-4B5F-ACE6-61B449AF0B1EQ40111993-F99C9DDB-8B06-4C79-BB80-516CB67604A1Q40976615-67CE5A87-DF87-4803-8FDD-A076DD335D43Q41748766-8826FBE4-F0BA-453E-A971-24D3BE8CD5A8Q46273551-DF4D6ABE-9009-43A4-AD2A-3D8A3ABCCD10Q53714289-1AFF0D8E-C0E4-4A14-91B5-CFD72A15DBA8
P2860
In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
In vitro pharmacodynamics of p ...... stant Acinetobacter baumannii.
@en
type
label
In vitro pharmacodynamics of p ...... stant Acinetobacter baumannii.
@en
prefLabel
In vitro pharmacodynamics of p ...... stant Acinetobacter baumannii.
@en
P2093
P2860
P356
P1476
In vitro pharmacodynamics of p ...... stant Acinetobacter baumannii.
@en
P2093
David P Nicolau
Joseph L Kuti
Mao Hagihara
Seth T Housman
P2860
P304
P356
10.1128/AAC.01624-13
P407
P577
2013-11-25T00:00:00Z